Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME.
THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy.
Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Company Details
- Employees
- 35
- Address
- Gaston Geenslaan 1, Leuven,3001,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.oxurion.com/
- HQ
- Leuven
Oxurion Nv Questions
Oxurion Nv's website is http://www.oxurion.com/
Oxurion Nv's LinkedIn profile is https://www.linkedin.com/company/oxurion
Oxurion Nv has
35 employees.
View email and phone details for 35
employees at Oxurion Nv.
Oxurion Nv's industry is
Biotechnology Research
Oxurion Nv's top competitors are
Eyebio,
Ablynx,
Breye Therapeutics Aps,
Celyad Oncology,
Confo Therapeutics,
Hopium,
Flamingo Therapeutics,
Findrive,
Astrivax Therapeutics,
Rewind Therapeutics.
Oxurion Nv's categories are Biotechnology Research
